CytomX Therapeutics
Quarterly Financials
| Values in thousands | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
Revenue | $5,963 | $18,658 | $50,917 | $38,093 |
Gross Profit | 5,963 | 18,658 | 50,917 | 38,093 |
EBITDA | -14,037 | -939 | 23,006 | 18,092 |
EBIT | -14,171 | -1,286 | 22,621 | 17,679 |
Net Income | -14,229 | -154 | 23,525 | 18,876 |
Net Change In Cash | 5,963 | 18,658 | 50,917 | 38,093 |
Free Cash Flow | -15,421 | -15,780 | -21,162 | -19,988 |
Cash | 34,185 | 49,041 | 47,604 | 38,052 |
Basic Shares | 165,004 | 129,075 | 87,150 | 80,099 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $138,103 | $101,214 | $53,163 | $69,573 |
Gross Profit | 138,103 | 101,214 | 53,163 | 69,573 |
EBITDA | 26,763 | -4,309 | -98,892 | -81,075 |
EBIT | 24,995 | -6,484 | -101,335 | -83,781 |
Net Income | 31,869 | -569 | -97,299 | -80,648 |
Net Change In Cash | 138,103 | 101,214 | 53,163 | 69,573 |
Cost of Revenue | 13,671 | 13,671 | ||
Free Cash Flow | -86,541 | -56,875 | -112,528 | -120,640 |
Cash | 38,052 | 17,171 | 193,650 | 205,530 |
Basic Shares | 84,745 | 73,808 | 65,739 | 64,146 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-12-31 | $0 |
2025-09-30 | -$0.09 |
2025-06-30 | -$0.001 |
2025-03-31 | $0.27 |
